TY - JOUR
T1 - Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease
AU - Mellor, Liliana F.
AU - Gago-Lopez, Nuria
AU - Bakiri, Latifa
AU - Schmidt, Felix N.
AU - Busse, Björn
AU - Rauber, Simon
AU - Jimenez, Maria
AU - Megías, Diego
AU - Oterino-Sogo, Sergio
AU - Sanchez-Prieto, Ricardo
AU - Grivennikov, Sergei
AU - Pu, Xinzhu
AU - Oxford, Julia
AU - Ramming, Andreas
AU - Schett, Georg
AU - Wagner, Erwin F.
N1 - Publisher Copyright:
©
PY - 2022/7/4
Y1 - 2022/7/4
N2 - Objectives S100A9, an alarmin that can form calprotectin (CP) heterodimers with S100A8, is mainly produced by keratinocytes and innate immune cells. The contribution of keratinocyte-derived S100A9 to psoriasis (Ps) and psoriatic arthritis (PsA) was evaluated using mouse models, and the potential usefulness of S100A9 as a Ps/PsA biomarker was assessed in patient samples. Methods Conditional S100A9 mice were crossed with DKO∗ mice, an established psoriasis-like mouse model based on inducible epidermal deletion of c-Jun and JunB to achieve additional epidermal deletion of S100A9 (TKO∗ mice). Psoriatic skin and joint disease were evaluated in DKO∗ and TKO∗ by histology, microCT, RNA and proteomic analyses. Furthermore, S100A9 expression was analysed in skin, serum and synovial fluid samples of patients with Ps and PsA. Results Compared with DKO∗ littermates, TKO∗ mice displayed enhanced skin disease severity, PsA incidence and neutrophil infiltration. Altered epidermal expression of selective pro-inflammatory genes and pathways, increased epidermal phosphorylation of STAT3 and higher circulating TNFα were observed in TKO∗ mice. In humans, synovial S100A9 levels were higher than the respective serum levels. Importantly, patients with PsA had significantly higher serum concentrations of S100A9, CP, VEGF, IL-6 and TNFα compared with patients with only Ps, but only S100A9 and CP could efficiently discriminate healthy individuals, patients with Ps and patients with PsA. Conclusions Keratinocyte-derived S100A9 plays a regulatory role in psoriatic skin and joint disease. In humans, S100A9/CP is a promising marker that could help in identifying patients with Ps at risk of developing PsA.
AB - Objectives S100A9, an alarmin that can form calprotectin (CP) heterodimers with S100A8, is mainly produced by keratinocytes and innate immune cells. The contribution of keratinocyte-derived S100A9 to psoriasis (Ps) and psoriatic arthritis (PsA) was evaluated using mouse models, and the potential usefulness of S100A9 as a Ps/PsA biomarker was assessed in patient samples. Methods Conditional S100A9 mice were crossed with DKO∗ mice, an established psoriasis-like mouse model based on inducible epidermal deletion of c-Jun and JunB to achieve additional epidermal deletion of S100A9 (TKO∗ mice). Psoriatic skin and joint disease were evaluated in DKO∗ and TKO∗ by histology, microCT, RNA and proteomic analyses. Furthermore, S100A9 expression was analysed in skin, serum and synovial fluid samples of patients with Ps and PsA. Results Compared with DKO∗ littermates, TKO∗ mice displayed enhanced skin disease severity, PsA incidence and neutrophil infiltration. Altered epidermal expression of selective pro-inflammatory genes and pathways, increased epidermal phosphorylation of STAT3 and higher circulating TNFα were observed in TKO∗ mice. In humans, synovial S100A9 levels were higher than the respective serum levels. Importantly, patients with PsA had significantly higher serum concentrations of S100A9, CP, VEGF, IL-6 and TNFα compared with patients with only Ps, but only S100A9 and CP could efficiently discriminate healthy individuals, patients with Ps and patients with PsA. Conclusions Keratinocyte-derived S100A9 plays a regulatory role in psoriatic skin and joint disease. In humans, S100A9/CP is a promising marker that could help in identifying patients with Ps at risk of developing PsA.
KW - cytokines
KW - inflammation
KW - psoriatic arthritis
UR - http://www.scopus.com/inward/record.url?scp=85134565419&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2022-222229
DO - 10.1136/annrheumdis-2022-222229
M3 - Article
C2 - 35788494
AN - SCOPUS:85134565419
SN - 0003-4967
VL - 81
SP - 1400
EP - 1408
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 10
ER -